IRIS
UCCELLI, ANTONIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 28.602
Totale 28.602
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 28.602
Totale 28.602
Salva come PNG Salva come JPEG
Città #
Genova 19.862
Genoa 3.205
Rapallo 2.878
Vado Ligure 2.571
Bordighera 86
Totale 28.602
Salva come PNG Salva come JPEG
Nome #
C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. 216
Composite MRI measures and short-term disability in patients with clinically isolated syndrome suggestive of MS 199
Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in Italy 189
Adult stem cells for spinal cord injury: what types and how do they work? 184
Multipotent mesenchymal stromal cells from amniotic fluid: solid perspectives for clinical application. 180
Neuroprotective features of mesenchymal stem cells. 178
Association of melanoma and natalizumab therapy in the Italian MS population: a second case report. 171
Blood-Brain Barrier Alterations in the Cerebral Cortex in Experimental Autoimmune Encephalomyelitis. 166
Early switch to fingolimod may decrease the risk of disease recurrence after natalizumab interruption 163
Immunotherapy for neurological diseases. 163
Unveiling the enigma of the CNS as a B-cell fostering environment. 159
CCL5-glutamate interaction in central nervous system: Early and acute presynaptic defects in EAE mice 159
Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. 158
Hereditary motor and sensory neuropathy with myelin outfolding: clinical, genetic and neuropathological study of three cases 158
Mechanisms of the adaptive immune response inside the central nervous system during inflammatory and autoimmune diseases. 157
Multipotent mesenchymal stromal cells for autoimmune diseases: teaching new dogs old tricks. 157
IFN-γ orchestrates mesenchymal stem cell plasticity through the signal transducer and activator of transcription 1 and 3 and mammalian target of rapamycin pathways 157
Antibodies against Epstein-Barr virus and herpesvirus type 6 are associated with the early phases of multiple sclerosis. 154
Investigation of paroxysmal dystonia in a patient with multiple sclerosis: a transcranial magnetic stimulation study. 153
Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. 153
Alpha-lipoic acid is effective in prevention and treatment of experimental autoimmune encephalomyelitis. 153
Quantitative 3D investigation of Neuronal network in mouse spinal cord model 152
Neurorepair with mesenchymal stem cells: hope or hype? 151
Urinary JCV-DNA Testing during Natalizumab Treatment May Increase Accuracy of PML Risk Stratification. 151
Human mesenchymal stem cells target adhesion molecules and receptors involved in T cell extravasation 151
Retinal nerve fibre layer measurements and optic nerve head analysis in multiple sclerosis patients. 150
Mesenchymal stem cells effectively modulate pathogenic immune response in experimental autoimmune encephalomyelitis. 150
Autologous stem cell transplantation as rescue therapy in malignant forms of multiple sclerosis. 150
17p11.2 duplication is a common finding in sporadic cases of charcot-marie-tooth type 1 150
The long-term effect of AHSCT on MRI measures of MS evolution: a five-year follow-up study. 150
In vitro VLA-4 blockade results in an impaired NK cell-mediated immune surveillance against melanoma 147
Immuno-therapeutic potential of haematopoietic and mesenchymal stem cell transplantation in MS. 147
The molecular signature of therapeutic mesenchymal stem cells exposes the architecture of the hematopoietic stem cell niche synapse. 147
Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis. 147
Catastrophic NAD(+) Depletion in Activated T Lymphocytes through Nampt Inhibition Reduces Demyelination and Disability in EAE 146
Nicotinamide Phosphoribosyltransferase (Nampt) Inhibitors As Therapeutics: Rationales, Controversies, Clinical Experience. 145
Sirt6 regulates dendritic cell differentiation, maturation, and function 144
Relapses after treatment with rituximab in a patient with multiple sclerosis and anti myelin-associated glycoprotein polyneuropathy. 142
Intense immunosuppression followed by autologous stem cell transplantation in severe multiple sclerosis. 142
Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multi-centre experience. 142
Stem cells for multiple sclerosis: promises and reality. 140
Can we switch microglia's phenotype to foster neuroprotection? Focus on multiple sclerosis. 140
Different MRI patterns in MS worsening after stopping fingolimod 140
Why should mesenchymal stem cells (MSCs) cure autoimmune diseases? 139
Autologous hematopoietic stem cell transplantation in multiple sclerosis: A phase II trial. 138
Human mesenchymal stem cells promote survival of T cells in a quiescent state. 138
Charcot-Marie-Tooth (CMT) 1a duplication at 17p11.2 in Italian families. 137
Effect of radial shock wave therapy on pain and muscle hypertonia: a double-blind study in patients with multiple sclerosis. 136
Alterations of glutamate release in the spinal cord of mice with experimental autoimmune encephalomyelitis 136
Selective impairments of motor sequence learning in multiple sclerosis patients with minimal disability 135
Regulation of human mesenchymal stem cell functions by an autocrine loop involving NAD+ release and P2Y11-mediated signaling. 135
Interferon-γ-dependent inhibition of B cell activation by bone marrow-derived mesenchymal stem cells in a murine model of systemic lupus erythematosus. 135
A major influence of the T cell receptor repertoire as compared to antigen processing-presentation in the selection of myelin basic protein epitopes in multiple sclerosis. 134
Phenotypic and functional characterisation of CCR7+ and CCR7- CD4+ memory T cells homing to the joints in juvenile idiopathic arthritis. 133
A restricted T cell response to myelin basic protein (MBP) is stable in multiple sclerosis (MS) patients. 133
A RCT Comparing Specific Intensive Cognitive Training to Aspecific Psychological Intervention in RRMS: The SMICT Study 133
Mesenchymal stem cells for the treatment of multiple sclerosis and other neurological diseases 132
Exploring Alzheimer's disease mouse brain through X-ray phase contrast tomography: From the cell to the organ 132
Immunological patterns identifying disease course and evolution in multiple sclerosis patients. 132
Reciprocal interactions between human mesenchymal stem cells and gammadelta T cells or invariant natural killer T cells. 131
Mesenchymal stem cells shape microglia effector functions through the release of CX3CL1 131
Mesenchymal stem cells for multiple sclerosis: does neural differentiation really matter? 130
Autologous haematopoietic stem-cell transplantation in multiple sclerosis: benefits and risks 129
Acute desipramine restores presynaptic cortical defects in murine experimental autoimmune encephalomyelitis by suppressing central CCL5 overproduction. 129
Intrathecal soluble HLA-E correlates with disease activity in patients with multiple sclerosis and may cooperate with soluble HLA-G in the resolution of neuroinflammation. 128
NG2, a common denominator for neuroinflammation, blood-brain barrier alteration, and oligodendrocyte precursor response in EAE, plays a role in dendritic cell activation 128
X-Ray Phase Contrast Tomography Reveals Early Vascular Alterations and Neuronal Loss in a Multiple Sclerosis Model 127
Autologous stem cell transplantation for severe autoimmune diseases: a 10-year experience. 125
Cingulum bundle alterations underlie subjective fatigue in multiple sclerosis 125
Mesenchymal stem cells impair in vivo T-cell priming by dendritic cells. 125
The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group. 125
Dysregulation of regulatory CD56bright NK cells/T cells interactions in multiple sclerosis 125
The therapeutic effect of mesenchymal stem cell transplantation in experimental autoimmune encephalomyelitis is mediated by peripheral and central mechanisms 124
T-cell trafficking in the central nervous system. 124
Frequency and risk factors of mitoxantrone-induced amenorrhea in multiple sclerosis: the FEMIMS study. 123
Primary varicella zoster infection associated with fingolimod treatment. 122
Low intensity lympho-ablative regimen followed by autologous hematopoietic stem cell transplantation in severe forms of multiple sclerosis: A MRI-based clinical study. 122
Central and peripheral nervous system complications following allogeneic bone marrow transplantation. 122
Anti-Glutamic Acid Decarboxylase Limbic Encephalitis Without Epilepsy Evolving Into Dementia With Cerebellar Ataxia 122
Neuroprotective mesenchymal stem cells are endowed with a potent antioxidant effect in vivo. 121
Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial. 121
Stem cells in inflammatory demyelinating disorders: a dual role for immunosuppression and neuroprotection. 120
Delivery to the central nervous system of a nonreplicative herpes simplex type 1 vector engineered with the interleukin 4 gene protects rhesus monkeys from hyperacute autoimmune encephalomyelitis. 120
Systemic administration of mesenchymal stem cells increases neuron survival after global cerebral ischemia in vivo (2VO). 120
Dramatic rebounds of MS during pregnancy following fingolimod withdrawal. 120
Teriflunomide treatment reduces B cells in patients with MS. 120
Relationship between retinal inner nuclear layer, age, and disease activity in progressive MS 120
Myelin basic protein intramolecular spreading without disease progression in a patient with multiple sclerosis. 120
Interindividual variability of cranioencephalic relationships as predicted by CT. 119
Costs and quality of life of multiple sclerosis in Italy. 119
Fumarates modulate microglia activation through a novel HCAR2 signaling pathway and rescue synaptic dysregulation in inflamed CNS 119
Characterization of mouse spinal cord vascular network by means of synchrotron radiation X-ray phase contrast tomography 119
Surrogate endpoints for EDSS worsening in multiple sclerosis. A meta-analytic approach. 119
Induction of experimental autoimmune encephalomyelitis in rats and immune response to myelin basic protein in lipid-bound form. 119
Clinical baseline factors predict response to natalizumab: their usefulness in patient selection. 118
Overexpression of sphingosine-1-phosphate receptors on reactive astrocytes drives neuropathology of multiple sclerosis rebound after fingolimod discontinuation 118
Intravenous immunoglobulin, plasmalymphocytapheresis and azathioprine in chronic progressive multiple sclerosis. 117
Treatment of multiple sclerosis with rituximab: A multicentric Italian-Swiss experience 117
Recommendations for the management of urinary disorders in multiple sclerosis: a consensus of the Italian Multiple Sclerosis Study Group. 116
Effect of copolymer-1 on serial gadolinium-enhanced MRI in relapsing remitting multiple sclerosis. 116
Totale 13.924
Salva come PNG Salva come JPEG
Categoria #
all - tutte 95.923
article - articoli 85.692
book - libri 355
conference - conferenze 6.978
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 2.898
Totale 191.846
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20204.643 0 0 0 0 0 0 1.219 606 724 1.127 719 248
2020/20212.373 169 199 233 221 147 200 149 230 193 291 169 172
2021/20223.469 107 213 319 457 152 193 143 755 174 317 118 521
2022/20233.468 329 292 41 362 558 581 21 221 593 37 362 71
2023/20242.391 110 246 70 274 181 405 239 158 126 71 147 364
2024/20253.009 339 480 212 467 811 685 15 0 0 0 0 0
Totale 29.240